Show simple item record

Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.

dc.contributor.authorAnderson, Heather
dc.contributor.authorScarffe, J Howard
dc.contributor.authorSutton, R N
dc.contributor.authorHickmott, E
dc.contributor.authorBrigden, D
dc.contributor.authorBurke, C
dc.date.accessioned2011-03-12T23:33:49Z
dc.date.available2011-03-12T23:33:49Z
dc.date.issued1984-07
dc.identifier.citationOral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. 1984, 50 (1):45-9 Br J Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid6378236
dc.identifier.urihttp://hdl.handle.net/10541/124412
dc.description.abstractForty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The dose of acyclovir was 200 mg four times daily for the duration of chemotherapy (six weeks). Of the 40 evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P less than 0.001), and the incidence of viral isolates from 70% on placebo to 5% on acyclovir (P less than 0.001).
dc.language.isoenen
dc.subject.meshAcyclovir
dc.subject.meshAdministration, Oral
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshClinical Trials as Topic
dc.subject.meshDouble-Blind Method
dc.subject.meshDoxorubicin
dc.subject.meshDrug Resistance, Microbial
dc.subject.meshFemale
dc.subject.meshHerpes Simplex
dc.subject.meshHumans
dc.subject.meshLeukemia, Lymphoid
dc.subject.meshLymphoma
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProcarbazine
dc.subject.meshRandom Allocation
dc.subject.meshVincristine
dc.titleOral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial.en
dc.typeArticleen
dc.identifier.eissn1532-1827
dc.contributor.departmentThe Department of Medical Oncology, Christie Hospital and Holt Radium Instituteen
dc.identifier.journalBritish Journal of Canceren
html.description.abstractForty-one patients receiving remission induction chemotherapy with vincristine, adriamycin and prednisolone (VAP) for high grade lymphoma or acute lymphoblastic leukaemia were entered into a double blind, placebo controlled trial of oral acyclovir prophylaxis against herpes simplex virus (HSV) infection. The dose of acyclovir was 200 mg four times daily for the duration of chemotherapy (six weeks). Of the 40 evaluable patients, 20 were randomised to each arm. Prophylactic oral acyclovir significantly reduced the incidence of clinical HSV infection from 60% on placebo to 5% acyclovir (P less than 0.001), and the incidence of viral isolates from 70% on placebo to 5% on acyclovir (P less than 0.001).


This item appears in the following Collection(s)

Show simple item record